// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Frexalimab, a CD40L Inhibitor, in Relapsing Multiple Sclerosis: Results from a Randomized Controlled Phase 2 Trial

Patrick Vermersch - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Ofatumumab Effectiveness and Safety in Relapsing Multiple Sclerosis Patients with Breakthrough Disease on Oral Fumarates or Fingolimod: Artios Interim Analysis

Riley Bove - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Fingolimod

Efficacy in Clinical and MRI Outcomes with Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis (MAGNIFY-MS)

Nicola De Stefano - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Multiple Sclerosis

Cladribine

Pregnancy Outcomes Following Exposure to Ofatumumab in Patients with MS: Results from the Prim Study

Riley Bove - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Congenital disorder

Congenital anomalies

ofatumumab Intravenous

Expanding the Connection between Cognition and Illness Intrusiveness in Multiple Sclerosis: The Contributions of Objective Versus Subjective and Resilience As a Moderator

Aprille Gangi - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Are Psychosocial Factors Associated with Physical Therapy Goal Accomplishment in Multiple Sclerosis?

Kayla Gomes - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Further Validation of the Multiple Sclerosis Resiliency Scale (MSRS)

Elizabeth S Gromisch - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Comparison of Physical Activity between Persons with Multiple Sclerosis with Lower Limb Weakness and Normal Strength

Heather M DelMastro - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Preoperative radiographic measurements can predict postoperative pancreatic fistula formation following pancreatoduodenectomy

E.W. Box - International Hepato-Pancreato-Biliary Association (IHPBA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Practice patterns and long-term outcomes among patients with pancreatic giant cell tumors

F.I. Macedo - International Hepato-Pancreato-Biliary Association (IHPBA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of adjuvant chemotherapy completion rates on outcomes following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma

K. Leslie - International Hepato-Pancreato-Biliary Association (IHPBA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

N/A

HepaT1ca - Quantitative Magnetic Resonance Imaging Predicts Individual Future Liver Performance after Liver Resection

D. Mole - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Can Peri-operative Lactate Kinetics Predict Liver Failure Following Major Liver Resection?

J. Alderman - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Pharmacological Activation of Nrf2 Enhances Metabolic Remodelling and Functional Liver Regeneration Following Major Hepatectomy

B.K.Y. Chan - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Adjuvant Therapy in Distal Cholangiocarcinoma Following Pancreaticoduodenectomy: A National Cancer Database Analysis

S. Kamarajah - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

N/A

Maximum Perioperative and Early Postoperative Arterial Lactate Concentrations Predict Post-hepatectomy Liver Failure and Associated Morbidity after Liver Resection

T. Niederwieser - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Role of Integrated Functional Assessment Pathway Using 99m Tc -Mebrofinate SPECT-CT Scan, ICG, Elastography and HVPG in Patients at Risk of Post Hepatectomy Liver Failure

B.V. Dasari - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Mebrofenin

Differences in Outcome of Laparoscopic Liver Surgery between Nationwide Daily Practice and High-volume Centers

B. Gorgec - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Recurrence Following Neoadjuvant Therapy and Resection for Pancreatic Ductal Adenocarcinoma: A Comprehensive Meta-Analysis and Meta-Regression

B. Ratnayake - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

N/A

The European Registry for Minimally Invasive Pancreatic Surgery (E-MIPS): First Year Experience

N. van der Heijde - International Hepato-Pancreato-Biliary Association (IHPBA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved